Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03994744
Recruitment Status : Recruiting
First Posted : June 21, 2019
Last Update Posted : August 28, 2019
Sponsor:
Collaborators:
Xiangya Hospital of Central South University
Innovent Biologics (Suzhou) Co. Ltd.
Information provided by (Responsible Party):
Lin Wu, Hunan Cancer Hospital

Tracking Information
First Submitted Date  ICMJE June 19, 2019
First Posted Date  ICMJE June 21, 2019
Last Update Posted Date August 28, 2019
Actual Study Start Date  ICMJE August 20, 2019
Estimated Primary Completion Date August 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 23, 2019)
  • Objective response rate of Sintilimab and Metformin(ORR) [ Time Frame: 1 year ]
    Assessing the response of treatment of each patient using RECIST 1.1 criteria, the investigators calculate the percentage of patients meet partial response (30% decrease in diameter) and complete response in the arm.
  • Safety of the combination therapy of Sintilimab and Metformin: CTCAE4.03 grading [ Time Frame: 2 year ]
    Incidence and severity of (serious) adverse events in each individual according to the CTCAE4.03 grading.
Original Primary Outcome Measures  ICMJE
 (submitted: June 20, 2019)
  • Objective response rate of Sintilimab and Metformin(ORR) [ Time Frame: 1 year ]
    Assessing the response of treatment of each patient using RECIST 1.1 criteria, we calculate the percentage of patients meet partial response (30% decrease in diameter) and complete response in the arm.
  • Safety of the combination therapy of Sintilimab and Metformin: CTCAE4.03 grading [ Time Frame: 2 year ]
    Incidence and severity of (serious) adverse events in each individual according to the CTCAE4.03 grading.
Change History Complete list of historical versions of study NCT03994744 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 20, 2019)
  • Median overall survival (OS) time of Sintilimab and Metformin [ Time Frame: 2 years ]
    Use K-M to estimate the median OS of single arm.
  • Median progression free survival(PFS) of Sintilimab and Metformin [ Time Frame: 1 year ]
    Use K-M to estimate the median PFS of single arm.
  • Median duration of response (DoR) of Sintilimab and Metformin [ Time Frame: 1 year ]
    Use K-M to estimate the median DoR of single arm.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
Official Title  ICMJE A Phase II Open-label, Single-arm Study Assessing the Efficacy and Safety of Combination Therapy of Sintilimab and Metformin With Relapsed PD-L1 Positive Small Cell Lung Cancer
Brief Summary

In this Single arm study, histologically or cytologically confirmed ED-stage small cell lung cancer (SCLC) patients resistant to or relapsed after standard chemotherapy will be enrolled to investigate the Efficacy and Safety of a Combination of Sintilimab and Metformin.

Primary outcome:

Objective response rate (ORR), Safety of the combination therapy

Secondary outcome:

Overall survival (OS), Progression-free survival (PFS), Duration of response(DOR),

Detailed Description

Exploratory Endpoints:

The association between the efficacy of the combination treatment and changes in CTC counts after administration of the treatment.

Evaluating the correlation between programmed death ligand 1 (PD-L1) expression derived from circulating tumor cells (CTC) and tumor tissue cells, and the predictive role of CTC PD-L1 expression in ED-SCLC.

The compositional changes in the gut microbiota after administration of the treatment and its association with the efficacy of the combination treatment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Intervention Model Description:

Patients fulfilling Eligibility Criteria will be included in our study. Participants will be given intravenous administration of Sintilimab (1200mg/3w).

Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).

Treatments will be administrated for one year or until disease progression, death, or unacceptable toxicity.

Regular follow-up and safety assessment: Patients were assessed for drug safety and treatment efficacy every 2 cycles (6 weeks) in the first 3 months after enrollment, and then evaluated every 4 cycles (12 weeks). Assessment of tumor response, adverse events. Follow-up until disease progression and patient death.

Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Small-cell Lung Cancer
  • Small Cell Lung Carcinoma
  • Small Cell Lung Cancer Recurrent
  • Small Cell Lung Cancer Extensive Stage
Intervention  ICMJE
  • Drug: PD-1 inhibitor
    Intravenous administration of Sintilimab (1200mg/3weeks)
    Other Names:
    • Sintilimab
    • IBI380
  • Drug: Metformin

    Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).

    To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week.

Study Arms  ICMJE Experimental: Sintilimab and Metformin

Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).

The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up.

Interventions:
  • Drug: PD-1 inhibitor
  • Drug: Metformin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 20, 2019)
68
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 1, 2022
Estimated Primary Completion Date August 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female patient, age≥18 and≤65;
  2. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
  3. The life expectancy of greater than 12 weeks;
  4. Participants must have histologically or cytologically confirmed metastatic or extended disease of SCLC (ED-SCLC).
  5. According to RECIST1.1, participants must have been confirmed Disease progression (within 6 months, confirmed by imaging test)after platinum-based doublet chemotherapy OR after (PFS>6 months, ) platinum-based doublet chemotherapy and refused to continue chemotherapy, OR after second-line or more lines of systemic chemotherapy limited disease SCLC (LD-SCLC) patients with disease progression after Synchronous chemoradiotherapy, must receive firstline systematic platinum-based doublet chemotherapy and refused to receive chemotherapy again.
  6. Evaluable or measurable lesion is required, defined as at least one lesion (not brain metastasis) that can be accurately measured based on RECIST 1.1;
  7. Participant need to provided tumor tissue (from an archival tumor sample obtained within 1 year or from a new biopsy sample) for PD-L1 immunohistochemical (IHC) assay, and PD-L1expression in more than 1% cells is required;
  8. Participant is able to the ability to swallow oral medications
  9. Participants have to meet the following criteria to ensure function of vital organs:

    Absolute neutrophil count (ANC) ≥1.5×109/L or White blood cell count >3.5×109/L;Platelets >80×109/L; Hemoglobin (HGB)≥90 g/L;Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤2.5 ×ULN; ALB≥2.8g/dL;Serum creatinine ≤ 1.5 x institutional ULN OR creatinine clearance ≥40 mL/min using the Cockcroft-Gault equation

  10. Participants must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) through the treatment, and for at least 180 days after the last dose of study treatment; Participants must have the ability to understand and be willing to sign a written informed consent document.

Exclusion Criteria:

  1. Participants who were diagnosed as mixed pathological type of small cell lung cancer
  2. Participants who had long-term use of metformin (>2 weeks) 6 months prior to study entry, or diagnosed with type-2 diabetes,
  3. Participants received treatment with anti-PD1, -PDL1, -CTLA4, -CD137 inhibitors before, or any therapy specifically targeting T-cell co-stimulation or checkpoint pathways.
  4. Participants received cellular immunotherapy before
  5. Participants with Uncontrolled intercurrent illness including, but not limited to:

    Ongoing or active infection; Known history of Human Immunodeficiency Virus (HIV) infection Acute or chronic active hepatitis B (HBV DNA >1*10^3 copies/ml or >200 IU/mL) or, acute or chronic active hepatitis C (with a positive Hepatitis C antibody test result) Active tuberculosis Congestive heart failure (Class III-IV, according to New York Heart Association classification), or and clinically significant Cardiac arrhythmia if poorly controlled; Uncontrolled arterial hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) Any arterial thrombosis, embolism, ischemia, myocardial infarction, unstable angina, or cerebrovascular accident within 6 months prior to enrollment,

  6. Participants with symptomatic Central nervous metastasis or meningeal carcinomatosis are excluded; Participants with asymptomatic brain metastases or with brain metastases that have been treated and stable in a subsequent scan are allowed to include if there is measurable lesion outside the Central nervous system and no history of intracranial hemorrhage, and not midbrain, pons, cerebellum, medulla or spinal cord metastasis, and do not need glucocorticoid therapy.
  7. Participants receiving glucocorticoid (>30 mg prednisone equivalent a day) or any Immunosuppressive drug within 14 days prior to study recruitment; Participants receiving inhaled or Topical corticosteroids, adrenal corticosteroid replacement therapy (>10 mg prednisone equivalent a day) are allowed if they have no active autoimmune disease
  8. Participants with a known additional malignancy (Except for Non-melanoma skin cancer and the following in situ carcinoma: in situ bladder carcinoma, in situ gastric carcinoma, in situ colonic carcinoma, in situ endometrial carcinoma, in situ cervical carcinoma /dysplasia, in situ melanoma carcinoma and in situ breast Carcinoma) unless they Maintained Complete Remission for at least 5 years and do not need corresponding treatment during the study
  9. Participants who have not recovered (i.e., ≤ Grade 1 according to NCI CTCAE V4or at baseline) from adverse effects due to a previously administered agent.
  10. Participants who have uncontrollable effusion, such as pleural and ascites that cannot be controlled by drainage or other treatment
  11. Patients who have active autoimmune diseases; excluding patients whose active autoimmune disease is caused by Vitiligo or asthma that is completely relieved in childhood and Patients with hypothyroidism requiring only hormone replacement therapy
  12. Patients with known Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
  13. Patients who are pregnant or breastfeeding,
  14. Patients who are allergic to monoclonal antibody drugs
  15. Patients who have contraindications to metformin including severe allergic reactions and intolerance
  16. Patients who are not eligible for this study, as Assessed by Investigator
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Lin Wu, Prof. +86 13170419973 wulin-calf@vip.163.com
Contact: Xingxiang Pu, Prof. +86 15874180022 pxx_1354@163.com
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03994744
Other Study ID Numbers  ICMJE HNCH-SCLC-2019260
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research
Supporting Materials: Study Protocol
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: please contact the principal investigator of this study or correspondence author of published wotk.
Responsible Party Lin Wu, Hunan Cancer Hospital
Study Sponsor  ICMJE Hunan Cancer Hospital
Collaborators  ICMJE
  • Xiangya Hospital of Central South University
  • Innovent Biologics (Suzhou) Co. Ltd.
Investigators  ICMJE
Principal Investigator: Lin Wu Hunan Cancer Hospital
PRS Account Hunan Cancer Hospital
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP